Variables | Univariate analysis | ||
---|---|---|---|
HR (95% CI) | p value | Log-rank p | |
Age (< 60 vs. ≥ 60) | 1.308 (0.292–5.855) | 0.725 | 0.725 |
Gender (male vs. female) | 1.657 (0.309–8.888) | 0.555 | 0.551 |
AJCC/UICC stage | Â | Â | 0.573 |
 I | Reference | 0.603 |  |
 II | 0.327 (0.02–5.240) | 0.429 |  |
 III | 0.966 (0.110–8.457) | 0.975 |  |
Length (< 5 vs. ≥ 5 cm) | 1.308 (0.292–5.855) | 0.725 | 0.960 |
Histopathology | Â | Â | 0.629 |
 Poorly differentiated | Reference | 0.641 |  |
 Moderately differentiated | 1.022 (0.105–9.920) | 0.985 |  |
 Undefined | 2.089 (0.216–20.179) | 0.524 |  |
CEA levels (< 5 vs. ≥ 5 ng/ml) | 1.483 (0.329–6.689) | 0.608 | 0.606 |
Distance to the anal verge (< 5 vs. ≥ 5 cm) | 0.432 (0.051–3.645) | 0.441 | 0.428 |
Courses of radiotherapy (one course vs. two course) | 1.075 (0.129–8.980) | 0.946 | 0.946 |
Chemotherapy regime (Capecitabine vs. Capoex/folfox) | 1.005 (0.195–5.187) | 0.996 | 0.996 |
Cycles of chemotherapy (≤ 4 vs. > 4) | 2.052 (0.241–17.441) | 0.510 | 0.502 |
Response to treatment (cCR vs. non-cCR) | 6.361 (1.380–29.328) | 0.018 | 0.007* |
Comorbidities (yes vs. no) | 39.757 (0.033–48,411.962) | 0.310 | 0.083 |